A randomized controlled study to compare the effects of angiotensin II type 1 receptor blockers (telmisartan vs candesartan vs valsartan) on the markers of cardiovascular risk in hypertensive patients with type 2 diabetes mellitus

A randomized controlled study to compare the effects of angiotensin II type 1 receptor blockers (telmisartan vs candesartan vs valsartan) on the markers of cardiovascular risk in hypertensive patients with type 2 diabetes mellitus - A clinical study to compare the effects of angiotensin II type 1 receptor blockers on cardiovascular risk markers in hypertensive patients with type 2 diabetes mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001689

Enrollment

300

Registered

2009-02-05

Start date

2005-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension with type 2 diabetes mellitus

Interventions

Telmisartan will be prescribed at 40 mg/day for 12 weeks. Candesartan will be prescribed at 8mg/day for 12 weeks. Varsartan will be prescribed at 80mg/day for 12 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. hypertensive patients who show systolic blood pressure > 130 mmHg or diastolic blood pressure > 80 mmHg, measured on an outpatient basis at the start of the observation period 2. diabetic patients who show HbA1c < 8.0% at the start of the observation period

Exclusion criteria

Exclusion criteria: 1. Patients being prescribed pioglitazone 2. Patients being treated with insulin 3. Patients with severe hepatic dysfunction 4. Patients with severe renal dysfunction 5. Patients with severe infection or severe injury 6. Patients requiring operative treatment 7. Patients with a past history of hypersensitiveness to these drugs 8. Pregnant and probably pregnant patients 9. Other patients judged as being inappropriate for the subjects of the study investigators

Design outcomes

Primary

Measure	Time frame
1. changes in adipocytokines 2. changes in high-sensitivity CRP 3. changes in PAI-I	—

Secondary

Measure	Time frame
1. changes in blood pressure levels measured on an outpatient basis 2. changes in blood pressure levels at home 3. changes in HOMA-R(fasting glucose, fasting insulin) 4. changes in HbA1c 5. changes in serum lipids levels (cholesterol, triglycerides, HDL cholesterol, FFA) 6. changes in urinary albumin levels	—

Countries

Japan

Contacts

Public ContactNobuaki Ozaki

Nagoya University Graduate School of Medicine Department of Endocrinology and Diabetes

n-ozaki@med.nagoya-u.ac.jp052-744-2142

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026